Genetic polymorphisms associated with liver fibrosis
View Patent ↗The present invention is based on the discovery of genetic polymorphisms that are associated with liver fibrosis and related pathologies. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection.
1. A method of determining whether a hepatitis C virus-infected human has an increased risk for developing liver fibrosis, comprising
a) testing nucleic acid from said human for the presence or absence of a polymorphism in gene TLR4 as represented by position 101 of SEQ ID NO: 18973 or its complement, and
b) determining that said human has an increased risk for developing liver fibrosis if said human has a C at position 101 of SEQ ID NO: 18973 or a G at position 101 of its complement.
2. The method of claim 1 in which said testing is performed using sequencing, 5′ nuclease digestion, molecular beacon assay, oligonucleotide ligation assay, size analysis, or single-stranded conformation polymorphism analysis.
3. The method of claim 1 in which said nucleic acid is a nucleic acid extract from a biological sample from said human.
4. The method of claim 3 in which said biological sample is blood, saliva, or buccal cells.
5. The method of claim 3 , further comprising preparing said nucleic acid extract from said biological sample prior to said testing step.
6. The method of claim 5 , further comprising obtaining said biological sample from said human prior to said preparing step.
7. The method of claim 1 , wherein said testing step comprises nucleic acid amplification.
8. The method of claim 7 , wherein said nucleic acid amplification is carried out by polymerase chain reaction.
9. The method of claim 1 in which said testing is carried out by using at least one detection reagent selected from the group consisting of detection reagents comprising the nucleotide sequence of SEQ ID NO:34275, detection reagents comprising the nucleotide sequence of SEQ ID NO:34276, and detection reagents comprising the nucleotide sequence of SEQ ID NO:34277.
10. The method of claim 1 , further comprising correlating the presence of said C or said G with an increased risk for developing liver fibrosis.
11. The method of claim 1 , wherein said testing is performed using an allele-specific method.
12. The method of claim 11 , wherein said allele-specific method is allele-specific probe hybridization, allele-specific primer extension, or allele-specific amplification.
13. The method of claim 1 , which is an automated method.